Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Notable Labs (NTBLQ)
OTHER OTC:NTBLQ
Holding NTBLQ?
Track your performance easily
NTBLQ Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.01 - $4.24
Previous Close$0.02
Volume7.03K
Average Volume (3M)2.64M
Market Cap
$172.91K
Enterprise Value-$2.13M
Total Cash (Recent Filing)$4.10M
Total Debt (Recent Filing)$1.79M
Price to Earnings (P/E)―
Beta2.39
Next Earnings
Aug 12, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.35
Shares Outstanding9,659,496
10 Day Avg. Volume62,328
30 Day Avg. Volume2,638,017
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)0.07
Price to Sales (P/S)0.62
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-6.81
Enterprise Value/Gross Profit-18.87
Enterprise Value/Ebitda0.44
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Clinical TrialsNotable Labs kicked off the volasertib AML trial, following the design of an accelerated volasertib clinical program that is moving directly into the PPMP-selected Ph2 trial portion.
Data UtilizationNTBL's ability to now use cryopreserved samples with PPMP unlocks significant data sources.
Regulatory ApprovalNTBL was cleared for the Ph2 volasertib program by the FDA in July and intends to enroll patients in the coming months.
Bears Say
Cash ConservationNotable Labs is conserving cash by pausing the planned volasertib Phase 2 trial and reducing its workforce and consultants by 65%.
Financing ConcernsFinancing requirements are a significant overhang as indicated by the company's filing of an S-1.
Lead Asset UncertaintyThe future of the lead asset volasertib is unclear.
---
Ownership Overview
16.12% Insiders
0.30% Mutual Funds
3.49% Other Institutional Investors
80.10% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
NTBLQ FAQ
What was Notable Labs’s price range in the past 12 months?
Notable Labs lowest stock price was $0.01 and its highest was $4.24 in the past 12 months.
What is Notable Labs’s market cap?
Currently, no data Available
When is Notable Labs’s upcoming earnings report date?
Notable Labs’s upcoming earnings report date is Aug 12, 2024 which is 104 days ago.
How were Notable Labs’s earnings last quarter?
Currently, no data Available
Is Notable Labs overvalued?
According to Wall Street analysts Notable Labs’s price is currently Overvalued.
Does Notable Labs pay dividends?
Notable Labs does not currently pay dividends.
What is Notable Labs’s EPS estimate?
Notable Labs’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Notable Labs have?
Notable Labs has 9,659,496 shares outstanding.
What happened to Notable Labs’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Notable Labs?
Among the largest hedge funds holding Notable Labs’s share is ARK Investment Management LLC. It holds Notable Labs’s shares valued at N/A.
---
Notable Labs Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 6.2%
Last 30 Days ▼ 6.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-99.55%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-55.35%
Trailing 12-Months
Company Description
Notable Labs
Vascular Biogenics Ltd. is in the clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of first-in-class treatments for cancer. It offers different programs for cancer and inflammatory disease patients such as vascular targeting system and Lecinoxoids. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel.
---
NTBLQ Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering NTBLQ
1 Year
1 Year Success Rate
0/3 ratings generated profit
1 Year Average Return
-96.63%
reiterated a buy rating 6 months ago
Copying Keay Nakae's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -96.63% per trade.
---